Dr Lingshi Tan, chairman and CEO of dMed, shares his strategic insights into the new era of Chinese biotech innovation and how it motivated him to leave Pfizer to establish dMed; the mission of dMed as ‘more than a CRO’ to support the growth of the Chinese biotech industry; their clinical development capabilities and how they are a partner of choice not only for Chinese companies looking to go global but also global companies looking to come to China; and his insights into current challenges and opportunities of the Chinese clinical development ecosystem.
When people talk about R&D, it conjures up the common image of drug breakthroughs miraculously emerging from laboratories. However, so much of the heavy lifting comes after that, during the clinical phase
